TY - JOUR
T1 - The current surgical treatment of pancreatic cancer in China
T2 - A national wide cross-sectional study
AU - Wu, Wenming
AU - Jin, Gang
AU - Wang, Chunyou
AU - Miao, Yi
AU - Wang, Huaizhi
AU - Lou, Wenhui
AU - Yu, Xianjun
AU - Sun, Bei
AU - Li, Haimin
AU - Qin, Renyi
AU - Wu, Zheng
AU - Wang, Weilin
AU - Xu, Kesen
AU - Wang, Lei
AU - Liang, Tingbo
AU - Hao, Chunyi
AU - Huang, Heguang
AU - Li, Yixiong
AU - Tan, Guang
AU - Zhao, Yongfu
AU - Hao, Jihui
AU - Wang, Yifan
AU - Peng, Chenghong
AU - Liu, Xubao
AU - Ou, Jinrui
AU - Yuan, Chunhui
AU - Wang, Xuefeng
AU - Yang, Yinmo
AU - Cai, Shouwang
AU - Guo, Kejian
AU - Jiang, Jianxin
AU - Yu, Xiao
AU - Wei, Junmin
AU - Li, Fei
AU - Wu, Xinmin
AU - Zhao, Yupei
N1 - Publisher Copyright:
© 2019 LWW. All rights reserved.
PY - 2019/3
Y1 - 2019/3
N2 - Objective:The aim of this study is to investigate the current status of pancreatic cancer patients undoing surgical treatment in China and to find ways to improve the survival of these patients in the future.Methods:This study is a national, multicenter, cross-sectional study in China. Information regarding pancreatic cancer patients undergoing surgical treatment from 34 high-volume tertiary IIIA level hospitals was collected and analyzed from the March 1, 2016 to the February 28, 2017.Results:In total, 2200 pancreatic cancer patients were enrolled from 34 tertiary IIIA level hospitals in 16 provinces across China. The male-to-female ratio was 1.5. More than 80% of the patients were between 50 and 70 years old. The top 4 symptoms were epigastric discomfort, abdominal pain, jaundice, and weight loss. Carbohydrate antigen 19-9 and carcinoembryonic antigen were elevated in 70.9% and 27.1% of patients, respectively. A multidisciplinary team (MDT) discussion was carried out for 35.0% of patients before surgery. The proportion of minimally invasive pancreatic surgeries was approximately 20%. A total of 83.4% of the operations achieved R0 resection, and the incidence of grade 3/4 postoperative complications was 7.7%. Only 13.4% of the patients received postoperative adjuvant chemotherapy. The percentage of pathological stage I tumors was only 24.5%.Conclusion:The majority of pancreatic cancer patients undergoing surgical resection in China are in an advanced stage. The MDT consultations for pancreatic cancer have not been widely carried out. R0 resection has been achieved in most cases, with relatively low incidence of serious complications, but minimally invasive pancreatic surgery should be further promoted. The application of postoperative chemotherapy remains low. This national, multicentre, cross-sectional study comprehensively presents the current status of pancreatic cancer patients undergoing surgical treatment and shows the road to improve survival of these patients in the future.
AB - Objective:The aim of this study is to investigate the current status of pancreatic cancer patients undoing surgical treatment in China and to find ways to improve the survival of these patients in the future.Methods:This study is a national, multicenter, cross-sectional study in China. Information regarding pancreatic cancer patients undergoing surgical treatment from 34 high-volume tertiary IIIA level hospitals was collected and analyzed from the March 1, 2016 to the February 28, 2017.Results:In total, 2200 pancreatic cancer patients were enrolled from 34 tertiary IIIA level hospitals in 16 provinces across China. The male-to-female ratio was 1.5. More than 80% of the patients were between 50 and 70 years old. The top 4 symptoms were epigastric discomfort, abdominal pain, jaundice, and weight loss. Carbohydrate antigen 19-9 and carcinoembryonic antigen were elevated in 70.9% and 27.1% of patients, respectively. A multidisciplinary team (MDT) discussion was carried out for 35.0% of patients before surgery. The proportion of minimally invasive pancreatic surgeries was approximately 20%. A total of 83.4% of the operations achieved R0 resection, and the incidence of grade 3/4 postoperative complications was 7.7%. Only 13.4% of the patients received postoperative adjuvant chemotherapy. The percentage of pathological stage I tumors was only 24.5%.Conclusion:The majority of pancreatic cancer patients undergoing surgical resection in China are in an advanced stage. The MDT consultations for pancreatic cancer have not been widely carried out. R0 resection has been achieved in most cases, with relatively low incidence of serious complications, but minimally invasive pancreatic surgery should be further promoted. The application of postoperative chemotherapy remains low. This national, multicentre, cross-sectional study comprehensively presents the current status of pancreatic cancer patients undergoing surgical treatment and shows the road to improve survival of these patients in the future.
KW - China
KW - Current status
KW - Pancreatic cancer
KW - Pancreatic surgery
KW - Treatment
UR - https://www.scopus.com/pages/publications/85079035711
U2 - 10.1097/JP9.0000000000000012
DO - 10.1097/JP9.0000000000000012
M3 - 文章
AN - SCOPUS:85079035711
SN - 2096-5664
VL - 2
SP - 16
EP - 21
JO - Journal of Pancreatology
JF - Journal of Pancreatology
IS - 1
ER -
可持续发展目标 3 良好健康与福祉